Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
When the risk of blood clots is high, therapy usually involves lowering the platelet count by using medications like hydroxyurea, interferon-alpha, and anagrelide.
Lonely people have unusually low numbers of a type of myeloid cell that generates what are known as interferon responses, which hamper viral replication.